MPM BioImpact’s Y-mAbs Therapeutics YMAB Stock Holding History

MPM BioImpact’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-443,702	Closed	-$6.4M	–	43
2022 Q3	$6.4M	Hold	443,702	–	–	1.52%	18
2022 Q2	$6.71M	Hold	443,702	–	–	1.86%	15
2022 Q1	$5.27M	Sell	443,702 -2,755	-0.6%	-$28.3K	1.41%	19
2021 Q4	$7.24M	Sell	446,457 -6,513	-1%	-$139K	1.32%	19
2021 Q3	$12.9M	Buy	452,970 +115,679	+34%	+$3.65M	2.01%	13
2021 Q2	$11.4M	Hold	337,291	–	–	1.87%	13
2021 Q1	$10.2M	Hold	337,291	–	–	1.28%	12
2020 Q4	$16.7M	Hold	337,291	–	–	2.93%	11
2020 Q3	$12.9M	Hold	337,291	–	–	3.12%	10
2020 Q2	$14.6M	Hold	337,291	–	–	3.87%	9
2020 Q1	$8.8M	Hold	337,291	–	–	5.38%	7
2019 Q4	$10.5M	Buy	+337,291	New	+$9.98M	3.74%	9

Other funds holding YMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact's YMAB Position: Q4 2022 in Review

MPM BioImpact sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 443,702 shares — an estimated $6.4M sold.

MPM BioImpact first reported a position in YMAB in Q4 2019 and held it in 12 quarters. The position peaked at $16.7M in Q4 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

MPM BioImpact reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
MPM BioImpact sold 443,702 Y-mAbs Therapeutics shares in Q4 2022, an estimated $6.4M.
MPM BioImpact first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 12 quarters.
MPM BioImpact's Y-mAbs Therapeutics position peaked at $16.7M in Q4 2020.
91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on MPM BioImpact's 13F filing for Q4 2022, filed 14 Feb 2023.